Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Did Reports of Side Effects Contribute to Drop in Bone Drug Use?

Lisa Rapaport  |  July 20, 2015

(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…

New Study Examines Pregnancy Risk Factors for Patients with Lupus

Lara C. Pullen, PhD  |  July 20, 2015

Important new findings show that a majority of women with inactive or stable SLE can have successful pregnancies without experiencing flares and give birth to infants who survive the neonatal period…

Certolizumab Pegol Effective for Treating Rheumatoid Arthritis

Reuters Staff  |  July 19, 2015

NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA…

Fulfilling ‘Three Wishes’ Helps ICU Staff Honor Dying Patients

Randi Belisomo  |  July 18, 2015

(Reuters Health)—Doctors and nurses in a Canadian intensive care unit found that asking dying patients—or their families—to make three simple wishes, and then fulfilling those wishes, helped bring peace to the end-of-life process and ease grief. Patients and families were invited to participate in the “Three Wishes Project” after a decision was made to withdraw…

Tofacitinib Not Tied to More Malignancies in RA Patients

David Douglas  |  July 17, 2015

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…

Bigger May Not Be Better for China’s ‘Super Hospitals’

Alexandra Harney  |  July 17, 2015

ZHENGZHOU, China (Reuters)—Just before midnight, the pavement outside the glowing high-rise towers of the First Affiliated Hospital of Zhengzhou University is littered with slumbering bodies. Splayed on colourful mats or tucked into folding cots, these are patients’ relatives. Inside, beds line hallways and crowd elevator lobbies, while relatives share gurneys with patients and doze in…

Family History Not Linked to Clinical Presentation, Treatment Response of RA

Will Boggs, MD  |  July 16, 2015

NEW YORK (Reuters Health)—Having a family history of rheumatoid arthritis (RA) does not appear to influence the clinical presentation or treatment response of RA to standard medications, researchers from Sweden report. “At first we were a bit surprised by our findings,” Dr. Thomas Frisell from Karolinska Institutet in Stockholm told Reuters Health by email. “Patients…

Teriparatide to Denosumab Switch Helpful in Osteoporosis

David Douglas  |  July 16, 2015

NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…

On Research Review Boards, Conflict-of-Interest Reporting Improves

Kathryn Doyle  |  July 16, 2015

(Reuters Health)—Many doctors who serve on hospital panels overseeing the ethics and safety of human research trials have industry relationships that may compromise their objectivity, but reporting these conflicts has become more common over the past 10 years, according to a new study. Physicians who serve on so-called institutional review boards (IRBs) may also be…

Greece Bans Export of 25 Drugs after Pharmacists’ Supply Warnings

Lefteris Karagiannopoulos  |  July 15, 2015

ATHENS (Reuters)—Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings by pharmacists that they faced difficulties in securing some supplies. A ministry spokeswoman said the Greek drugs regulator had told a meeting at the ministry on Friday—when the pharmacists made their warnings—that there had…

  • « Previous Page
  • 1
  • …
  • 573
  • 574
  • 575
  • 576
  • 577
  • …
  • 817
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences